SHINTARO HIRATA

Last Updated :2024/02/01

Affiliations, Positions
Hiroshima University Hospital(Medical), Professor
Other Contact Details
1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan
TEL : (+81)82-257-1583 FAX : (+81)82-257-1584

Basic Information

Major Professional Backgrounds

  • 1998/05/06, 2000/03/31, National Hospital Organization Kure Medical Center, Clinical Resident
  • 2000/04/01, 2002/03/31, Tokyo Women's Medical University, Doctor
  • 2002/04/01, 2003/03/30, Hiroshima University, Hospital, Clinical Fellow
  • 2007/10/01, 2008/03/31, Hiroshima University, Hospital, Clinical Fellow
  • 2008/04, 2011/03, University of Occupational and Environmental Health, Japan, Assistant Professor
  • 2011/04, 2012/03, Wakamatsu Hospital of the University of Occupational and Environmental Health, Japan, Lecturer
  • 2012/04, 2015/03, University of Occupational and Environmental Health, Japan, Lecturer
  • 2015/04, 2016/08, University of Occupational and Environmental Health, Japan, Lecturer
  • 2016/09/01, 2020/03/31, Hiroshima University, Hospital, Lecturer
  • 2020/04/01, 2021/10/31, Hiroshima University, Hospital, Associate Professor
  • 2021/11/01, Hiroshima University, Hospital, Professor

Educational Backgrounds

  • Hiroshima University, Faculty of Medicine, Japan, 1992/04, 1998/03
  • Hiroshima University, Graduate School of Biomedical Sciences, Japan, 2003/04, 2009/09

Academic Degrees

  • Doctor of Philosophy in Medical Science, Hiroshima University

Educational Activity

  • [Bachelor Degree Program] School of Medicine : Program of Medicine : Medicine
  • [Master's Program] Graduate School of Biomedical and Health Sciences : Division of Integrated Health Sciences
  • [Doctoral Program] Graduate School of Biomedical and Health Sciences : Division of Biomedical Sciences : Program of Medicine

In Charge of Primary Major Programs

  • Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Collagenous pathology / Allergology

Research Keywords

  • Medicine, Rheumatology, Clinical Immunology, Rheumatoid Arthritis, Collagen Vascular Disease

Affiliated Academic Societies

  • Japan College of Rheumatology
  • The Japanese Society of Internal Medicine
  • The Japan Society for Clinical Immunology
  • Japanese Society for Immunology
  • The Japanese Respiratory Society
  • The Japanese Society of Inflammation and Regeneration
  • Japanese Society  for Sjogren's Syndrome
  • Japanese Society of Allergology
  • osteoimmunology

Educational Activity

Course in Charge

  1. 2023, Graduate Education (Doctoral Program) , First Semester, Advanced Research on Clinical Immunology and Rheumatology
  2. 2023, Graduate Education (Doctoral Program) , Second Semester, Advanced Research on Clinical Immunology and Rheumatology
  3. 2023, Undergraduate Education, Year, Clinical diagnosis and treatment II
  4. 2023, Undergraduate Education, Intensive, Introduction to clinical clerkship
  5. 2023, Undergraduate Education, Intensive, Practice for medical research
  6. 2023, Undergraduate Education, Intensive, Practice of Medicine I
  7. 2023, Undergraduate Education, Intensive, Practice of Medicine II
  8. 2023, Graduate Education (Master's Program) , Second Semester, General Clinical Medicine and Dentistry
  9. 2023, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar on Clinical Immunology and Rheumatology
  10. 2023, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar on Clinical Immunology and Rheumatology

Research Activities

Academic Papers

  1. Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication, MODERN RHEUMATOLOGY, 33(1), 21-35, 20230103
  2. Non-drug and surgical treatment algorithm and recommendations for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication, MODERN RHEUMATOLOGY, 33(1), 36-45, 20230103
  3. Portal Vein Thrombosis as a Cause of Undetermined Thrombocytopenia with Liver Dysfunction in a Patient with Eosinophilic Granulomatosis with Polyangiitis, INTERNAL MEDICINE, 62(1), 123-127, 2023
  4. Expression of factor XIII originating from synovial fibroblasts and macrophages induced by interleukin-6 signaling, INFLAMMATION AND REGENERATION, 43(1), 20230106
  5. Does exercise therapy improve patient-reported outcomes in rheumatoid arthritis? A systematic review and meta-analysis for the update of the 2020 JCR guidelines for the management of rheumatoid arthritis, MODERN RHEUMATOLOGY, 32(1), 96-104, 20220105
  6. Dupilumab as an adjunct treatment for a patient with steroid-dependent immunoglobulin G4-related disease complicated by asthma: a case report, JOURNAL OF ASTHMA, 59(12), 2395-2401, 20221110
  7. Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study, RHEUMATOLOGY, 61(11), 4273-4285, 20221102
  8. Importance of anti-centromere antibodies in the diagnosis of Sjogren's syndrome, JOURNAL OF ORAL SCIENCE, 64(4), 324-326, 202210
  9. Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19, JOURNAL OF CLINICAL IMMUNOLOGY, 42(7), 1360-1370, 202210
  10. Cancellous bone-like tissue replacement from calcinosis in patients with systemic sclerosis with multiple external root resorption, BONE REPORTS, 16, 202206
  11. Comprehensive risk analysis of postoperative complications in patients with rheumatoid arthritis for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis, MODERN RHEUMATOLOGY, 32(2), 296-306, 20220228
  12. Patients' perspectives of rheumatoid arthritis treatment: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines, MODERN RHEUMATOLOGY, 32(2), 307-312, 20220228
  13. Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis, MODERN RHEUMATOLOGY, 32(1), 74-86, 20220105
  14. Patient satisfaction with total joint replacement surgery for rheumatoid arthritis: a questionnaire survey for the 2020 update of the Japan college of rheumatology clinical practice guidelines, MODERN RHEUMATOLOGY, 32(1), 121-126, 20220105
  15. Hypertrophic pachymeningitis in ANCA-associated vasculitis: a cross-sectional and multi-institutional study in Japan (J-CANVAS), ARTHRITIS RESEARCH & THERAPY, 24(1), 204, 20220823
  16. Late-onset rheumatoid arthritis registry study, LORIS study: study protocol and design, BMC RHEUMATOLOGY, 6(1), 90-90, 20221226
  17. Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis, MODERN RHEUMATOLOGY, 32(2), 313-322, 20220228
  18. N-1-methylpseudouridine-incorporated mRNA enhances exogenous protein expression and suppresses immunogenicity in primary human fibroblast-like synoviocytes, CYTOTECHNOLOGY, 74(4), 503-514, 202208
  19. C-reactive protein and ground-glass opacity as predictors for intractable interstitial lung disease in patients with systemic sclerosis under cyclophosphamide treatment regardless of concomitant glucocorticoids, MODERN RHEUMATOLOGY, 32(1), 141-148, 20220105
  20. Safe Introduction of Hydroxychloroquine Focusing on Early Intolerance Due to Adverse Drug Reactions in Patients with Systemic Lupus Erythematosus, Intern Med, 2022
  21. Nailfold capillaries and myositis-specific antibodies in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis, RHEUMATOLOGY, 61(5), 2006-2015, 20220505
  22. Comment on: Nailfold capillaries and myositis-specific antibodies in anti-melanoma differentiation-associated gene 5 antibody-positive DM. Reply, Rheumatology (Oxford), 61(5), e122-e124, 2022
  23. Exacerbation of systemic lupus erythematosus after receiving mRNA-1273-based coronavirus disease 2019 vaccine, J Dermatol, 49(6), e199-e200, 2022
  24. Comment on: Combination of immunosuppressive therapy and nintedanib improves capillaroscopic changes in systemic sclerosis-interstitial lung disease: a case report, Rheumatol Adv Pract, 61(1), rkac024, 2022
  25. Bilateral facial nerve palsy responded to immunosuppressive therapy in a patient with eosinophilic granulomatosis with polyangiitis, Rheumatol Adv Pract, 6(3), rkac073, 2022
  26. The Lipopolysaccharide Mutant Re-LPS Is a Useful Tool for Detecting LPS Contamination in Rheumatoid Synovial Cell Cultures, Pathobiology, 89(2), 92-100, 2022
  27. Cryoglobulinemic Vasculitis Associated with Monoclonal Gammopathy of Undetermined Significance Developed after Sustained Virologic Response of Hepatitis C: A Case Report, Intern Med, 2022
  28. The Efficacy of Amenamevir for the Treatment of Disseminated Herpes Zoster Complicated with Probable Varicella-zoster Pneumonia in an Immunocompromised Patient, INTERNAL MEDICINE, 61(11), 1785-1788, 2022
  29. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis - A systematic review and meta-analysis, MODERN RHEUMATOLOGY, 31(1), 61-69, 20210102
  30. 2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases, MODERN RHEUMATOLOGY, 31(1), 29-33, 20210102
  31. Lower CH50 as a predictor for intractable or recurrent lupus enteritis: A retrospective observational study, MODERN RHEUMATOLOGY, 31(3), 643-648, 20210504
  32. Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study, PULMONARY PHARMACOLOGY & THERAPEUTICS, 67, 202104
  33. Tapering and discontinuation of oral glucocorticoids without deterioration of disease status in patients with rheumatoid arthritis under a stable treatment, MODERN RHEUMATOLOGY, 31(4), 803-808, 20210704
  34. The clinical characteristics and predictors of severe digital ischemia in patients with anti-aminoacyl transfer RNA synthetase antibodies, JOURNAL OF DERMATOLOGY, 48(7), 1044-1051, 202107
  35. Immunoglobulin D-kappa multiple myeloma in a patient with rheumatoid arthritis: a case report and review of the literature, MODERN RHEUMATOLOGY CASE REPORTS, 5(1), 22-28, 20210102
  36. Rapid changes of nailfold capillary abnormalities during treatment for a patient with dermatomyositis complicated by lung cancer: a case report, MODERN RHEUMATOLOGY CASE REPORTS, 5(1), 95-100, 20210102
  37. Asymptomatic coronary aneurysms in a patient with eosinophilic granulomatosis with polyangiitis who developed a digital gangrene, MODERN RHEUMATOLOGY CASE REPORTS, 5(1), 130-136, 20210102
  38. Capsule endoscopy findings reflect the gastrointestinal conditions of patients with systemic sclerosis, SCIENTIFIC REPORTS, 11(1), 20211011
  39. A Rare Case of IgG4-Related Disease Presenting as a Unilateral Severe Dacryoadenitis Complicated by Hypophysitis and Hypertrophic Pachymeningitis., J Clin Rheumatol, 27, S571-S573, 2021
  40. Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial, ANNALS OF THE RHEUMATIC DISEASES, 79(1), 94-102, 202001
  41. Tumour necrosis factor alpha promotes secretion of 14-3-3 eta by inducing necroptosis in macrophages, ARTHRITIS RESEARCH & THERAPY, 22(1), 20200212
  42. Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis, ARTHRITIS & RHEUMATOLOGY, 72(3), 488-498, 202003
  43. TGF beta 1 Regulates Human RANKL-Induced Osteoclastogenesis via Suppression of NFATc1 Expression, INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 21(3), 202002
  44. Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study, MODERN RHEUMATOLOGY, 30(3), 442-449, 20200503
  45. Impaired expression of innate immunity-related genes in IgG4-related disease: A possible mechanism in the pathogenesis of IgG4-RD, MODERN RHEUMATOLOGY, 30(3), 551-557, 20200503
  46. Activin A Expressed in Rheumatoid Synovial Cells Downregulates TNF alpha-Induced CXCL10 Expression and Osteoclastogenesis, PATHOBIOLOGY, 87(3), 198-207, 202006
  47. Elevating the role of carers in rheumatoid arthritis management in the Asia-Pacific region, INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 23(7), 898-910, 202007
  48. 5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study, MODERN RHEUMATOLOGY, 30(5), 799-806, 20200902
  49. Effect ofPorphyromonas gingivalisinfection on gut dysbiosis and resultant arthritis exacerbation in mouse model, ARTHRITIS RESEARCH & THERAPY, 22(1), 20201019
  50. Serum CXCL10 levels are associated with better responses to abatacept treatment of rheumatoid arthritis, CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 38(5), 956-963, 2020
  51. Coexisting TIF1 gamma-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1 gamma Antibody-positive Dermatomyositis, INTERNAL MEDICINE, 59(20), 2553-2558, 2020
  52. A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and the effectiveness of abatacept in rheumatoid arthritis patients, SCIENTIFIC REPORTS, 10(1), 19717, 20201112
  53. Predictive factors for structural remission using abatacept: Results from the ABROAD study, MODERN RHEUMATOLOGY, 29(3), 406-412, 20190504
  54. Tumour necrosis factor alpha augments the inhibitory effects of CTLA-4-Ig on osteoclast generation from human monocytes via induction of CD80 expression, CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 196(3), 392-402, 201906
  55. Large-vessel vasculitis associated with PEGylated granulocyte-colony stimulating factor, NETHERLANDS JOURNAL OF MEDICINE, 77(6), 224-226, 201907
  56. Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis, INTERNAL MEDICINE, 58(21), 3129-3132, 2019
  57. Multiple External Root Resorption of Teeth as a New Manifestation of Systemic Sclerosis-A Cross-Sectional Study in Japan, JOURNAL OF CLINICAL MEDICINE, 8(10), 1628, 201910
  58. Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with IgG4-related disease, RHEUMATOLOGY, 57(3), 514-524, 201803
  59. Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients, CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 36(3), 462-470, 2018
  60. Clinical practice guideline for Sjogren's syndrome 2017, MODERN RHEUMATOLOGY, 28(3), 383-408, 2018
  61. Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study, SCIENTIFIC REPORTS, 8(1), 10262, 20180706
  62. Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching., Clin Immunol, 191, 67-74, 2018
  63. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus., Lupus, 27(5), 802-811, 2018
  64. Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis., Rheumatology (Oxford), 57(1), 164-174, 2018
  65. Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis, ARTHRITIS RESEARCH & THERAPY, 20(1), 240, 20181026
  66. Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study), ANNALS OF THE RHEUMATIC DISEASES, 77(9), 1268-1275, 201809
  67. Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren's syndrome with other sets of criteria in Japanese patients., Ann Rheum Dis, 76(12), 1980-1985, 2017
  68. Integrating patients' perceptions into clinical practice guidelines for the management of rheumatoid arthritis in Japan., Mod Rheumatol, 27(6), 924-929, 2017
  69. A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease., Mod Rheumatol, 27(5), 849-854, 2017
  70. The process of collecting and evaluating evidences for the development of Guidelines for the management of rheumatoid arthritis, Japan College of Rheumatology 2014: Utilization of GRADE approach, MODERN RHEUMATOLOGY, 26(2), 175-179, 2016
  71. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching, ANNALS OF THE RHEUMATIC DISEASES, 75(7), 1321-1327, 2016
  72. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study), ANNALS OF THE RHEUMATIC DISEASES, 75(11), 1917-1923, 2016
  73. Clinically relevant radiographic progression in joint destruction in RA patients with abnormal MMP-3 or high levels of CRP despite 1-year treatment with infliximab, MODERN RHEUMATOLOGY, 26(6), 807-812, 2016
  74. Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice, MODERN RHEUMATOLOGY, 26(6), 850-856, 2016
  75. Effectiveness of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjogren's syndrome Endocrinopathy) trial, MODERN RHEUMATOLOGY, 26(6), 891-899, 2016
  76. Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study., Clin Exp Rheumatol, 34(5), 834-841, 2016
  77. New assessment method in rheumatoid arthritis, Nihon Rinsho, 74(6), 931-937, 2016
  78. Assessment of disease activity in rheumatoid arthritis by multi-biomarker disease activity (MBDA) score., Nihon Rinsho Meneki Gakkai Kaishi, 39(1), 37-41, 2016
  79. ★, Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study., Ann Rheum Dis, 74(2), 389-395, 2015
  80. Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus, RHEUMATOLOGY, 54(3), 405-412, 2015
  81. ★, A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study, MODERN RHEUMATOLOGY, 25(3), 344-349, 2015
  82. Combination therapy for early rheumatoid arthritis: a treatment holiday perspective., Expert Rev Clin Pharmacol, 8(1), 115-122, 2015
  83. Pulmonary infections following immunosuppressive treatments during hospitalization worsen the short-term vital prognosis for patients with connective tissue disease-associated interstitial pneumonia, MODERN RHEUMATOLOGY, 25(4), 609-614, 2015
  84. Postoperative complications in patients with rheumatoid arthritis using a biological agent - A systematic review and meta-analysis., Mod Rheumatol, 25(5), 672-678, 2015
  85. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry., Arthritis Res Ther, 17, 74, 2015
  86. Decreased Expression of Innate Immunity-Related Genes in Peripheral Blood Mononuclear Cells from Patients with IgG4-Related Disease., PLoS One, 10, e0126582, 2015
  87. ★, Serum 14-3-3 eta level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab, ARTHRITIS RESEARCH & THERAPY, 17, 280, 2015
  88. Efficacy and safety of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward Sjogren's syndrome Endocrinopathy (ROSE) trial an open-label, one-year, prospective study Interim analysis of 32 patients for 24 weeks, Mod Rheumatol, 25(2), 187-193, 2015
  89. Postoperative complications in patients with rheumatoid arthritis using a biological agent - A systematic review and meta-analysis, MODERN RHEUMATOLOGY, 25(5), 672-678, 2015
  90. JAK Inhibition Significantly Reduced Fibrogenesis in Rheumatoid Arthritis Patients, ARTHRITIS & RHEUMATOLOGY, 67, 2015
  91. 14-3-3 eta Positive Status and Higher Titres Are Associated with More Severe RA, ARTHRITIS & RHEUMATOLOGY, 67, 2015
  92. Efficacy and safety of abatacept for patients with Sjogren's syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward Sjogren's syndrome Endocrinopathy (ROSE) trial an open-label, one-year, prospective study Interim analysis of 32 patients for 24 weeks, MODERN RHEUMATOLOGY, 25(2), 187-193, 2015
  93. Combination therapy for early rheumatoid arthritis: a treatment holiday perspective, EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 8(1), 115-122, 2015
  94. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry, ARTHRITIS RESEARCH & THERAPY, 17, 2015
  95. Imaging assessment of bone and cartilage destruction in rheumatoid arthritis, Clin Calcium, 25(12), 1777-1785, 2015
  96. Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study, MODERN RHEUMATOLOGY, 24(1), 42-51, 2014
  97. Efficacy and safety of reducing duration of infliximab infusion, MODERN RHEUMATOLOGY, 24(2), 275-280, 2014
  98. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events, RHEUMATOLOGY, 53(5), 914-918, 2014
  99. Primary and secondary surveys on epidemiology of Sjogren's syndrome in Japan, MODERN RHEUMATOLOGY, 24(3), 464-470, 2014
  100. Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia (R) as Biological Intensive Treatment for RA (ORBIT) study, MODERN RHEUMATOLOGY, 24(5), 754-762, 2014
  101. Characteristic Phenotype of Peripheral Blood Lymphocytes in Patients with IgG4-Related Disease, Comparing to Primary Sjogren Syndrome and Healthy Controls., ARTHRITIS & RHEUMATOLOGY, 66, S1225-S1225, 2014
  102. 14-3-3eta Informs Joint Pathological Mechanisms of Treatment Response to Assist with T2T Strategies, ARTHRITIS & RHEUMATOLOGY, 66(12), 3537-3537, 2014
  103. Intensive Intervention Can Lead to a Treatment Holiday from Biological DMARDs in Patients with Rheumatoid Arthritis, DRUGS, 74(18), 2129-2139, 2014
  104. Validation of different sets of criteria for the diagnosis of Sjogren's syndrome in Japanese patients, MODERN RHEUMATOLOGY, 23(2), 219-225, 2013
  105. Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs, MODERN RHEUMATOLOGY, 23(2), 284-296, 2013
  106. A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology, MODERN RHEUMATOLOGY, 23(2), 297-303, 2013
  107. Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjogren's syndrome, MODERN RHEUMATOLOGY, 23(2), 401-405, 2013
  108. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study, RHEUMATOLOGY, 52(7), 1202-1207, 2013
  109. Repeated High Or Low Multi-Biomarker Disease Activity (VECTRA (R) DA Algorithm) Scores Associated With Radiographic Outcomes In Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors, ARTHRITIS AND RHEUMATISM, 65, S616-S617, 2013
  110. Is It Possible to Withdraw Biologics From Therapy in Rheumatoid Arthritis?, CLINICAL THERAPEUTICS, 35(12), 2028-2035, 2013
  111. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study, ARTHRITIS RESEARCH & THERAPY, 15(5), 2013
  112. Discontinuation of biologics in patients with rheumatoid arthritis., Clin Exp Rheumatol, 2013
  113. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study), MODERN RHEUMATOLOGY, 22(3), 327-338, 2012
  114. A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/beta(2) glycoprotein I and anti-phosphatidylserine/prothrombin autoantibodies, MODERN RHEUMATOLOGY, 22(5), 769-773, 2012
  115. Discontinuation of Adalimumab without Functional and Radiographic Damage Progression After Achieving Sustained Remission in Patients with Rheumatoid Arthritis (the HONOR study): 1-Year Results., ARTHRITIS AND RHEUMATISM, 64(10), S333-S333, 2012
  116. A Multi-Biomarker Disease Activity (VECTRA (TM) DA Algorithm) Score Reflects Clinical Disease Activity and Structural Changes in Rheumatoid Arthritis Patients Treated with Tocilizumab., ARTHRITIS AND RHEUMATISM, 64(10), S897-S897, 2012
  117. Correlation of A Multi-Biomarker Disease Activity (VECTRA (TM) DA) Score with Clinical Disease Activity and Its Components with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Tofacitinib., ARTHRITIS AND RHEUMATISM, 64(10), S914-S915, 2012
  118. A Multi-Biomarker Disease Activity (VECTRA (TM) DA Algorithm) Score Reflects Clinical Disease Activity and Tracks Responses in Patients with Rheumatoid Arthritis Treated with Either Adalimumab, Etanercept, and Infliximab, ARTHRITIS AND RHEUMATISM, 64(10), S1130-S1130, 2012
  119. Phenotypic changes of lymphocyte in a patient with IgG4-related disease after corticosteroid therapy, ANNALS OF THE RHEUMATIC DISEASES, 71(12), 2058-U179, 2012
  120. Steroid psychosis in a polyarteritis nodosa patient successfully treated with risperidone: tracking serum brain-derived neurotrophic factor levels longitudinally, ANNALS OF GENERAL PSYCHIATRY, 11, 2012
  121. [Rheumatoid arthritis: progress in diagnosis and treatment. Topics: V. Evaluation; 2. Evaluation of joint destruction by plain X-ray in rheumatoid arthritis., Nihon Naika Gakkai Zasshi, 101(10), 2893-2898, 2012
  122. A Novel Multi-Biomarker Disease Activity Score (Vectra (TM) DA algorithm score) Reflects Clinical Disease Activity Score and Health Assessment Questionnaire for Rheumatoid Arthritis in the BeSt Study, ARTHRITIS AND RHEUMATISM, 63(10), S132-S132, 2011
  123. Tofacitinib Reduces Interferon-gamma and Interleukin-17 Production From CD4+T Cells in Patients with Rheumatoid Arthritis., ARTHRITIS AND RHEUMATISM, 63(10), S496-S496, 2011
  124. A Multi-Biomarker Disease Activity (Vectra DA) Algorithm Score for Rheumatoid Arthritis Predicts Radiographic Progression in the BeSt Study, ARTHRITIS AND RHEUMATISM, 63(10), S630-S630, 2011
  125. A Multi-Biomarker Disease Activity Score (Vectra (TM) DA algorithm score) Reflects Clinical Disease Activity and Tracks Response in a Japanese Rheumatoid Arthritis Population Treated with Anti-TNF Therapy, ARTHRITIS AND RHEUMATISM, 63(10), S878-S878, 2011
  126. Discontinuation of Adalimumab Without Functional and Structural Progress After Attaining Remission in Patients with Rheumatoid Arthritis, ARTHRITIS AND RHEUMATISM, 63(10), S962-S962, 2011
  127. Lymphocyte transformation test is not helpful for the diagnosis of methotrexate-induced pneumonitis in patients with rheumatoid arthritis, CLINICA CHIMICA ACTA, 407(1-2), 25-29, 2009
  128. A case of pulmonary asbestosis presenting with temporal arteritis involving multiple medium-sized vessels, MODERN RHEUMATOLOGY, 18(1), 100-104, 2008
  129. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease., Rheumatology (Oxford), 45, 1046-1047, 2006
  130. Neutropenic enterocolitis in lung cancer: a report of two cases and a review of the literature., Intern Med,, 44, 467-470, 2005
  131. Myocardial dysfunction in a patient with adult-onset Still's disease (AOSD)., Clin Exp Rheumatol,, 22, 506-507, 2004

Invited Lecture, Oral Presentation, Poster Presentation

  1. Tapering and Discontinuing Prednisolone Without Deteriorated Disease Control by Optimizing Methotrexate in Patients with Rheumatoid Arthritis Under Stable Treatment – 2-year Results in the Real-world Clinical Practice –, Hirata S, Omoto T, Kohno H, Watanabe H, Yukawa K, Tokunaga T, Kuranobu T, Oi T, Yoshida Y, Sugimoto T, Mokuda S, Oda K, Nojima T, Sugiyama E, ACR/ARHP Annual Meeting (ACR 2019), 2019/11/08, Without Invitation, English
  2. Practical Optimization of Methotrexate Dose Improves Disease Control of Rheumatoid Arthritis Despite Reduction or Discontinuation of Oral Glucocorticoids, Shintaro Hirata, Kei Araki, Hiroki Kohno, Kazutoshi Yukawa, Tadahiro Tokunaga, Tatsuomi Kuranobu, Katsuhiro Oi, Yusuke Yoshida, Tomohiro Sugimoto, Keisuke Oda, Takaki Nojima, Eiji Sugiyama, ACR/ARHP Annual Meeting (ACR 2018), 2018/10/19, Without Invitation, English
  3. Optimisation of methotrexate dose induced successful reduction of glucocorticoids without impaired disease control in patients with rheumatoid arthritis, S. Hirata, T. Kondo, K. Yukawa, T.Tokunaga, T.Kuranobu, K. Oi, Y. Yoshida, M. Funaki, K. Oda, T. Nojima, E. Sugiyama, Annual European Congress of Rheumatology (EULAR 2018), 2018/06/13, Without Invitation, English
  4. Multicenter 14-3-3ETA biomarker reproducibility; the japanese experience, S. Hirata,M. Kaneda,T. Isayama,Y. Gu,A. Marott,W. P. Maksymowyc,Y. Tanaka, Annual European Congress of Rheumatology (EULAR 2017), 2017/06/14, Without Invitation, English
  5. 14-3-3ETA predicts joint damage progression and flaring after adalimumab discontinuation, S. Hirata,M. Kaneda,T. Isayama,Y. Gu,A. Marott,W. P. Maksymowyc,Y. Tanaka, Annual European Congress of Rheumatology (EULAR 2017), 2017/06/14, Without Invitation, English
  6. Predicting Flare and Sustained Clinical Remission after Adalimumab Withdrawal Using the Multi-Biomarker Disease Activity (MBDA) Score, Shintaro Hirata,Xingbin Wang,CC Hwang,Ippei Miyagawa,Satoshi Kubo,Kazuhisa Nakano,Shingo Nakayamada,Kazuyoshi Saito,Nadine A. Defranoux,Yoshiya Tanaka, 2016/11/11, Without Invitation, English
  7. Lower Baseline 14-3-3eta Levels Are Associated with Better Patient Reported Outcomes in Tocilizumab Treated Patients, Shintaro Hirata,Anthony Marotta,Kentaro Hanami, and Yoshiya Tanaka, 2016/11/11, Without Invitation, English
  8. Predictive Value of The Multi-Biomarker Disease Activity (MBDA) Score for Flare and Sustained Remission in The Honor Study, S.Hirata,S.Tang,C.C. Hwang,I. Miyagawa, S. Kubo,K. Nakano,S. Nakayamada,K. Saito, N.A. Defranoux,Y. Tanaka, 2016/06/08, Without Invitation, English
  9. Baseline Serum 14-3-3 ETA Independently Predicts Clinically Important Improvements in HAQ-DI in Patients with Rheumatoid Arthritis Treated with Tocilizumab, S.Hirata,K. Hanami,A. Marotta,Y. Tanaka, 2016/06/08, Without Invitation, English
  10. BAnti-JAK Is Anti-Fibrotic in Patients with Rheumatoid Arthritis, S. Hirata,N.S. Gudmann,S. Kubo,M. Karsdal,A.C. Bay-Jensen,Y. Tanaka, 2016/06/08, Without Invitation, English

Awards

  1. 2015/04/23, International Workshop Award, Japan College of Rheumatology

Social Activities

History as Peer Reviews of Academic Papers

  1. 2022, Rheumatology and Therapy, Others, 5
  2. 2022, Clinical Rheumatology, Others, 4
  3. 2022, Scandinavian Journal of Rheumatology, Others, 1
  4. 2022, Arthritis Research & Therapy, Others, 1
  5. 2022, International Journal of Rheumatic Diseases, Others, 2
  6. 2022, Modern Rheumatology Case Reports, Others, 1
  7. 2021, Rheumatology and Therapy, Others, 3
  8. 2021, International Journal of Rheumatic Diseases, Others, 2
  9. 2021, Modern Rheumatology Case Reports, Others, 2
  10. 2021, Rheumatology International, Others, 1
  11. 2021, Rheumatology, Others, 11
  12. 2021, Modern Rheumatology, Others, 12
  13. 2021, Arthritis Research & Therapy, Others, 3
  14. 2021, Cytokine, Others, 2
  15. 2021, Clinical Rheumatology, Others, 1
  16. 2020, Rheumatology, Others, 4
  17. 2020, The Journal of Rheumatology, Others, 1
  18. 2020, Internal Medicine, Others, 2
  19. 2020, Plos One, Others, 1
  20. 2020, Modern Rheumatology, Others, 9
  21. 2020, Journal of Clinical Rheumatology, Others, 4
  22. 2020, International Journal of Rheumatic Diseases, Others, 2
  23. 2020, Modern Rheumatology Case Reports, Others, 3
  24. 2019, Plos One, Others, 1
  25. 2019, Arthritis Research & Therapy, Others, 3
  26. 2019, ACR Open Rheumatology, Others, 1
  27. 2019, International Journal of Rheumatic Diseases, Others, 3
  28. 2019, Journal of Clinical Rheumatology, Others, 2
  29. 2019, Modern Rheumatology, Others, 11
  30. 2019, Modern Rheumatology Case Reports, Others, 6
  31. 2019, Rheumatology, Others, 5
  32. 2019, Rheumatology International, Others, 3
  33. 2018, Modern Rheumatology, Others, 7
  34. 2018, BMJ Open, Others, 3
  35. 2018, Arthritis Research & Therapy, Others, 3
  36. 2018, Geriatrics & Gerontology International, Others, 3
  37. 2018, Rheumatology, Others, 2
  38. 2018, International Journal of Rheumatic Diseases, Others, 2
  39. 2018, Modern Rheumatology Case Reports, Others, 2
  40. 2018, Rheumatology International, Others, 1
  41. 2018, Arthritis Care & Research, Others, 1
  42. 2017, Modern Rheumatology, Others, 13
  43. 2017, Plos One, Others, 4
  44. 2017, The Journal of Rheumatology, Others, 2
  45. 2017, Rheumatology, Others, 1
  46. 2017, Journal of Bone and Mineral Metabolism, Others, 1
  47. 2017, Inflammation Research, Others, 1
  48. 2017, Rheumatology International, Others, 1
  49. 2017, Journal of Clinical Rheumatology, Others, 1
  50. 2017, Arthritis Care & Research, Others, 1
  51. 2016, Modern Rheumatology, Others, 8
  52. 2016, Rheumatology International, Others, 6
  53. 2016, Arthritis Care & Research, Others, 4
  54. 2016, Rheumatology, Others, 2
  55. 2016, Inflammation Research, Others, 2
  56. 2015, Modern Rheumatology, 5
  57. 2015, Rheumatology International, 4
  58. 2015, Internal Medicine, 4
  59. 2015, Arthritis Care & Research, 4
  60. 2015, Journal of Bone and Mineral Metabolism, 1
  61. 2014, Modern Rheumatology, 7
  62. 2014, Rheumatology International, 4
  63. 2014, Arthritis Care & Research, 3
  64. 2014, Internal Medicine, 2
  65. 2014, The Journal of Rheumatology, 1
  66. 2013, The Journal of Rheumatology, 1
  67. 2011, Modern Rheumatology, 1
  68. 2010, Modern Rheumatology, 1